Management

Zydus Cadila files anti-diabetic drug application with DCGI

Healthcare services provider Zydus Cadila has filed an application before the Drugs Controller General of India (DCGI) for its anti-diabetic drug. The company has filed an investigational new drug (IND) application before the DCGI for its ZYD1 drug, used in the treatment of diabetes, Cadila Healthcare, the flagship company of Zydus Cadila group, said in a filing to the Bombay Stock Exchange. The global anti-diabetic market is estimated at Rs 24 billion dollars in 2008.

Cosmetic Surgeons commented:

Healthcare services provider Zydus Cadila has filed an application before the Drugs Controller General of India (DCGI) for its anti-diabetic drug

20.02.2012


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
'India key to our future plans'
Dilip Kumar Jha / Mmbai August 11, 2009, 0:24 IST
Popular Articles

'Bottom-up market ripe for investors'
In the final interview in the current series of Smart Portfolios, Phani Sekhar, fund manager, PMS, Angel broking talks about his investing strategy, sectors he is bullish on and how investors should approach the market.

India should manufacture equipment of N-industry: Kakodkar
The Indian private industries who are keen to participate in the large growth of civil nuclear power programme in the country should immediately concentrate on the manufacturing of equipments to become a major N-supply chain provider and later even exporters, Chairman, Atomic Energy Commission, Dr Anil Kakodkar said.

© Copyright 2009